Document:

Exhibit
10.11

 

[FORM
OF] COMMON STOCK AND WARRANT PURCHASE AGREEMENT

 

THIS
COMMON STOCK AND WARRANT PURCHASE AGREEMENT (this

“Agreement”),
is made as of is made as of ____, by and among SOS HYDRATION INC., a Nevada corporation (the “Company”) and the investors
listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the “Purchasers”).

 

The
parties hereby agree as follows:

 

1.
Purchase and Sale of Common Stock.

 

1.1
Sale and Issuance of Common Stock and Warrant.

 

(a)
Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the applicable Closing (as defined below)
and the Company agrees to sell and issue to each Purchaser at the Closing that number of shares of Common Stock,

$.001
par value per share (the “Common Stock”), set forth opposite each Purchaser’s name on Exhibit A, at a
purchase price of $3.54 per share. The shares of Common Stock issued to the Purchasers pursuant to this Agreement shall be referred to
in this Agreement as the “Shares.”

 

(b)
A warrant will be issued for the purchase of Common Stock for each share of Common Stock purchased on a one for one basis (the “Initial
Warrant”). The Initial Warrant will be exercisable at $3.54, it will have a cashless exercise feature and, unless extended
pursuant to Section 1.1(d), will expire seven point five (7.5) years from the Closing (the “Initial Warrant Expiration Date”).

 

(c)
If the Company’s gross revenue for the calendar year ended December 31, 2023 is not $9,400,000 or greater, the Purchaser will receive
a subsequent warrant (the “Subsequent Warrant”) for one additional share of Common Stock for each share of Common
Stock purchased by Purchaser pursuant to this Agreement. The Subsequent Warrant will be exercisable at $3.54, it will have a cashless
exercise feature and, unless extended pursuant to Section 1.1(d), will expire on the Initial Warrant Expiration Date.

 

(d)
If the Company’s gross revenue for the calendar year ended December 31, 2023 is not $6,266,667 or greater, the Initial Warrant
Expiration Date, applicable to the Initial Warrant and the Subsequent Warrant, shall be extended to twelve (12) years from the Closing.
In such case, the Company and Purchaser shall enter into the Common Stock Purchase Warrant Amendment in the form attached as Exhibit
D to this Agreement.

 

Example:
Purchaser purchases 100 shares at $3.54 per share. Purchaser receives an Initial Warrant for 100 Shares with a strike price of $3.54
per share, and a term of 7.5 years.

 

(i)  
If gross revenue of the Company for calendar
year 2023 is $9,400,000, the Company does not issue to the Purchaser an additional warrant and there is no amendment to the Initial Warrant
Expiration Date.

    	 

    	 

    

(ii)  
 If gross revenue of the Company for calendar
year 2023 is $9,300,000, the Company would issue the Subsequent Warrant to the Purchaser for 100 shares at a strike price of

$3.54
per share, with the same expiration date as the Initial Warrant (7.5 years from the Closing Date).

 

(iii)  
If gross revenue of the Company for calendar
year 2023 is $6,000,000, the Company would issue the Subsequent Warrant to the Purchaser for 100 shares at a strike price of

$3.54
per share, with an expiration date of 12 years from the Closing Date and the Initial Warrant would also be amended with an extended term
of 12 years from the Closing Date.

 

The
Company’s gross revenue for purposes of this Agreement, including Section 1.1, will be derived solely from the Company’s
consolidated audited financial statements for the year ended December 31, 2023. The consolidated audited financials also include the
total gross sales from the SOS UK subsidiary converted to USD, and will be binding on the Purchaser. If required pursuant to Section
1.1, the Company will issue the Subsequent Warrant and make any amendment to the Initial Warrant Expiration Date within thirty (30) days
of the issuance of the Company’s audited financial statements for the year ended December 31, 2023.

 

The
form of warrant is attached as Exhibit B.

 

1.2
Closing; Delivery.

 

(a)
The initial purchase and sale of the Shares shall take place remotely via the exchange of documents and signatures, at 9 a.m. PST, on
June 1, 2022, or at such other time and place as the Company and the Purchasers mutually agree upon, orally or in writing (which time
and place are designated as the “Initial Closing”). In the event there is

more
than one closing, the term “Closing” shall apply to each such closing unless otherwise specified.

 

(b)
At each Closing, the Company shall deliver to each Purchaser an electronic certificate representing the Shares being purchased by such
Purchaser at such Closing against payment of the purchase price therefor by wire transfer to a bank account designated by the Company.

 

1.3
Sale of Additional Shares of Common Stock.

 

(a)
After the Initial Closing, the Company may sell, on the same terms and conditions as those contained in this Agreement, up to a total
of 310,734 Shares (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or similar recapitalization
affecting such shares) of Common Stock (the “Additional Shares”), to one (1) or more purchasers (the “Additional
Purchasers”) approved by the Board of Directors, provided that (i) such subsequent sale is consummated prior to twenty-one
(21) days after the Initial Closing (ii) each Additional Purchaser becomes a party to this Agreement by executing and delivering a counterpart
signature page to each of this Agreement. Exhibit A to this Agreement shall be updated to reflect the number of Additional Shares
purchased at each such Closing and the parties purchasing such Additional Shares.

    	 

    	 

    

1.4
Use of Proceeds.

 

In
accordance with the directions of the Company’s Board of Directors, the Company will use the proceeds from the sale of the Shares
for working capital, business development, product development, operational expenses and other general corporate purposes.

 

1.5
Defined Terms Used in this Agreement.

 

In
addition to the terms defined above, the following terms used in this Agreement shall be construed to have the meanings set forth or
referenced below.

 

(a)
“Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is
controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer,
director or trustee of such Person, or any venture capital fund or registered investment company now or hereafter existing that is controlled
by one (1) or more general partners, managing members or investment advisers of, or shares the same management company or investment
adviser with, such Person.

 

(b)
“Code” means the Internal Revenue Code of 1986, as

amended.

 

(c)
“Company Intellectual Property” means all patents,

patent
applications, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark
applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes, similar
or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses
in, to and under any of the foregoing, and in any and all such cases that are owned or used by the Company in the conduct of the Company’s
business as now conducted and as presently proposed to be conducted.

 

(d)
“Disqualification Event” means a “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii)
promulgated under the Securities Act.

 

(e)
“Key Employee” means any executive-level employee (including division director and vice president-level positions)
as well as any employee or consultant who either alone or in concert with others develops, invents, programs or designs any Company Intellectual
Property.

 

(f)
“Knowledge” including the phrase “to the Company’s knowledge” shall mean the actual knowledge of
the following officer: James Mayo, Chief Executive Officer. Additionally, for purposes of Section 2.8, the Company shall be deemed to
have “knowledge” of a patent right if the Company has actual knowledge of the patent right or would be found to be on notice
of such patent right as determined by reference to United States patent laws.

    	 

    	 

    

(g)
“Material Adverse Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities,
financial condition, property, or results of operations of the Company.

 

(h)
“Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.

 

(i)
“Purchaser” means each of the Purchasers who is initially a party to this Agreement and any Additional Purchaser who
becomes a party to this Agreement at a subsequent Closing under Section 1.2(b).

 

(j)
“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

(k)
“Transfer Stock” means those Shares owned by a Purchaser which the Purchaser intends to sell.

 

2.
Representations and Warranties of the Company.

 

The
Company hereby represents and warrants to each Purchaser that, except as set forth on the Disclosure Schedule attached as Exhibit
C to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following
representations are true and complete as of the date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall
be arranged in sections corresponding to the numbered and lettered sections contained in this Section 2, and the disclosures in any section
of the Disclosure Schedule shall qualify other sections in this Section 2 only to the extent it is readily apparent from a reading of
the disclosure that such disclosure is applicable to such other sections.

 

For
purposes of these representations and warranties (other than those in Sections 2.2, 2.3, 2.4, 2.5, and 2.6), the term the “Company”
shall include any subsidiaries of the Company, unless otherwise noted herein.

 

2.1
Organization, Good Standing, Corporate Power and

Qualification.

 

The
Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite
corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. The Company is duly
qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material
Adverse Effect.

 

2.2
Capitalization.

 

(a)               
The authorized capital of the Company consists, immediately
prior to the Initial Closing, of:

 

(i)                
200,000,000 shares of common stock, no par value per share (the “Common Stock”), as of May 31, 2022, there are 5,996,963
shares of which are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have
been duly authorized, are fully paid and non-assessable and were issued in compliance with all applicable federal and state securities
laws.

    	 

    	 

    

 

(b)
As of May 31, 2022, the Company has issued 480,382 options to purchase Common Stock of which 221,856 options have vested and are exercisable.
The Company has issued 1,841,589 warrants to purchase Common Stock at a weighted exercise price of $3.25 per share with a weighted average
life of 7.61 years, of which 1,070,045 warrants are vested and exercisable. The Company has granted the underwriter warrants to purchase
Common Stock in a number and at a price that will be based on the shares, warrants, or units as sold in the Initial Public Offering (“IPO”).

 

(c)
Except for the securities and rights described in Section 2.2(b) of this Agreement and Section 2.2(c) of the Disclosure Schedule, there
are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights)
or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock, or any securities convertible
into or exchangeable for shares of Common Stock or Common Stock. All outstanding shares of the Company’s Common Stock and all shares
of the Company’s Common Stock underlying outstanding options are subject to (i) a right of first refusal in favor of the Company
upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market standoff agreement of not
less than one hundred eighty (180) days following the Company’s initial public offering pursuant to a registration statement filed
with the Securities and Exchange Commission under the Securities Act.

 

(d)
The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by this Agreement.

 

2.3
Subsidiaries.

 

Except
for a subsidiary in the U.K., the Company does not currently own or control, directly or indirectly, any interest in any other corporation,
partnership, trust, joint venture, limited liability company, association, or other business entity.

 

2.4
Authorization.

 

All
corporate action required to be taken by the Company’s Board of Directors and stockholders in order to authorize the Company to
enter into this Agreement, and to issue the Shares at the Closing has been taken. All action on the part of the officers of the Company
necessary for the execution and delivery of this Agreement, the performance of all obligations of the Company under this Agreement to
be performed as of the Closing, and the issuance and delivery of the Shares has been taken. This Agreement, when executed and delivered
by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the Company in accordance
with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) as limited
by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies.

    	 

    	 

    

 

2.5
Valid Issuance of Shares.

 

The
Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly
issued, fully paid and non-assessable and free of restrictions on transfer other than restrictions on transfer under this Agreement,
applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser. Assuming the accuracy of
the representations of the Purchasers in Section 3 of this Agreement the Shares will be issued in compliance with all applicable federal
and state securities laws.

 

2.6
Governmental Consents and Filings.

 

Assuming
the accuracy of the representations made by the Purchasers in Section 3 of this Agreement, no consent, approval, order or authorization
of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required
on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for filings
pursuant to applicable securities laws, which have been made or will be made in a timely manner.

 

2.7
Litigation.

 

The
Company is not a party to and is not named as a subject to the provisions of any order, writ, injunction, judgment or decree of any court
or government agency or instrumentality.

 

2.8
Intellectual Property.

 

(a)
The Company owns or possesses or can acquire on commercially reasonable terms sufficient legal rights to all Company Intellectual Property
without any known conflict with, or infringement of, the rights of others, including prior employees or consultants. The Company has
not received any communications alleging that the Company has violated, or by conducting its business, would violate any of the patents,
trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person.

 

(b)
To the Company’s knowledge, no product or service marketed or sold (or proposed to be marketed or sold) by the Company violates
or will violate any license or infringes or will infringe any intellectual property rights of any other party in a manner which would
create reasonable damages from such infringement above US$5,000 owed by the Company to the alleged infringed person.

 

(c)
Other than with respect to commercially available software products under standard end-user object code license agreements, there are
no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company
Intellectual Property.

    	 

    	 

    

(d)
The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled
electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with the Company’s
business for all software programs whereby any claim of infringement would not constitute a reasonable claim of damages by the infringed
person in excess of US$5,000 owed by the Company.

 

(e)
Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the Company’s
business as now conducted and as presently proposed to be conducted and all intellectual property rights that he, she or it solely or
jointly conceived, reduced to practice, developed or made during the period of his, her or its employment or consulting relationship
with the Company that (i) relate, at the time of conception, reduction to practice, development, or making of such intellectual property
right, to the Company’s business as then conducted or as then proposed to be conducted, (ii) were developed on any amount of the
Company’s time or with the use of any of the Company’s equipment, supplies, facilities or information or (iii) resulted from

the
performance of services for the Company. To the Company’s knowledge, it will not be necessary to use any inventions of any of its
employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Company, including prior employees
or consultants.

 

(f)
No government funding, facilities of a university, college, other educational institution or research center, or funding from third parties
was used in the development of any Company Intellectual Property. No Person who was involved in, or who contributed to, the creation
or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational
institution or research center in a manner that would affect Company’s rights in the Company Intellectual Property.

 

2.9
Compliance with Other Instruments.

 

The
Company is not in violation or default (i) of any provisions of its Articles of Incorporation or Bylaws, (ii) of any instrument, judgment,
order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to
which it is a party or by which it is bound that is required to be listed on the Disclosure Schedule where breach of such agreement,
contract or purchase order would constitute a Material Adverse Effect, or (v) to its knowledge, of any provision of federal or state
statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect. The execution, delivery
and performance of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in any such
violation or be in conflict with or constitute, with or without the passage of time and giving of notice, either (i) a default under
any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii) an event which results in the creation
of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material
permit or license applicable to the Company.

    	 

    	 

    

2.10
Agreements; Actions.

 

(a)
Except for this Agreement, there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company
is a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments to, the Company in excess of
$10,000, (ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company, (iii)
the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit the Company’s
exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Company with
respect to infringements of proprietary rights.

 

(b)
The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series
of its capital stock, (ii) incurred any indebtedness for money borrowed as of May 12, 2022 in excess of

$725,158
in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for business expenses, or (iv) sold, exchanged
or otherwise disposed of any of its assets or rights, other than in the ordinary course of business. For the purposes of (a) and (b)
of this Section 2.10, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving
the same Person (including Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose
of meeting the individual minimum dollar amounts of such section.

 

(c)
The Company is not a guarantor or indemnitor of any

indebtedness
of any other Person.

 

2.11
Certain Transactions.

 

(a)
Other than (i) standard employee benefits generally made available to all employees, standard employee offer letters and Confidential
Information Agreements (as defined below), (ii) standard director and officer indemnification agreements approved by the Board of Directors,
(iii) the purchase of shares of the Company’s capital stock and the issuance of options to purchase shares of the Company’s
Common Stock, in each instance, approved in the written minutes of the Board of Directors (previously provided to the Purchasers or their
respective counsel), and (iv) this Agreement, there are no agreements, understandings or proposed transactions between the Company and
any of its officers, directors, consultants or Key Employees, or any Affiliate thereof.

 

(b)
The Company is not indebted, directly or indirectly, to any of its directors, officers or employees or to their respective spouses or
children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the
ordinary course of business or employee relocation expenses and for other customary

employee
benefits made generally available to all employees. None of the Company’s directors, officers or employees, or any members of their
immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Company or, to the Company’s
knowledge, have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship
with any of the Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct
or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business
relationship, or any firm or corporation which competes with the Company except that directors, officers, employees or stockholders of
the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly traded companies that
may compete with the Company; or (iii) financial interest in any material contract with the Company.

    	 

    	 

    

 

2.12
Rights of Registration and Voting Rights.

 

Except
for the Bridge Loan that the Company entered into in June 2021, the Company is not under any obligation to register under the Securities
Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities.

 

2.13
Property.

 

The
property and assets that the Company owns are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except
for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary
course of business and do not materially impair the Company’s ownership or use of such property or assets. With respect to the
property and assets it leases, the Company, to the Company’s knowledge, is in compliance with such leases and, to the Company’s
knowledge, holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the lessors of such property
or assets. The Company does not own any real property.

 

2.14
Financial Statements.

 

The
Company has delivered to each Purchaser its audited financial statements for the calendar year 2021 and unaudited financial statements
for the three-month period ended on March 31, 2022 (the “Financial Statements”). The Financial Statements have been
prepared in accordance with generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout
the periods indicated, except that the unaudited Financial Statements may not contain all footnotes required by GAAP. The Financial Statements
fairly present in all material respects the financial condition and operating results of the Company as of the dates, and for the periods,
indicated therein, subject in the case of the unaudited Financial Statements to normal year-end audit adjustments. Except as set forth
in the Financial Statements, the Company has no material liabilities or obligations, contingent or otherwise, other than (i) liabilities
incurred in the ordinary course of business subsequent to the Financial Statements; (ii) obligations under contracts and commitments
incurred in the ordinary course of business; and (iii) liabilities obligations of a type or nature not required under GAAP to be reflected
in the Financial Statements, which, in all such cases, individually and in the aggregate would not have a Material Adverse Effect. The
Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP.

    	 

    	 

    

2.15
Employee Matters.

 

(a)
To the Company’s knowledge, none of its employees is obligated under any contract (including licenses, covenants or commitments
of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially
interfere with such employee’s ability to promote the interest of the Company or that would conflict with the Company’s business.
Neither the execution or

delivery
of this Agreement, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s
business as now conducted and as presently proposed to be conducted, will, to the Company’s knowledge, conflict with or result
in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which
any such employee is now obligated.

 

(b)
The Company is not delinquent in payments to any of its employees, consultants, or independent contractors for any wages, salaries, commissions,
bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such
employees, consultants or independent contractors. The Company has complied in all material respects with all applicable state and federal
equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification
and collective bargaining. The Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet
due to such governmental entity all amounts required to be withheld from employees of the Company and is not liable for any arrears of
wages, taxes, penalties or other sums for failure to comply with any of the foregoing.

 

(c)
To the Company’s knowledge, no Key Employee intends to terminate employment with the Company or is otherwise likely to become unavailable
to continue as a Key Employee. The Company does not have a present intention to terminate the employment of any of the foregoing. Except
for the employment of the CEO, the employment of each employee of the Company is terminable at the will of the Company. Except as set
forth in Section 2.15(c)(i) of the Disclosure Schedule or as required by law, upon termination of the employment of any such employees,
no severance or other payments will become due. Except as set forth in Section 2.15(c)(ii) of the Disclosure Schedule, the Company has
no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination
of employment services.

 

(d)
The Company has not made any representations regarding equity incentives to any officer, employee, director or consultant that are inconsistent
with the share amounts and terms set forth in the minutes of meetings of (or actions taken by unanimous written consent by) the Company’s
Board of Directors.

 

(e)
Each former Key Employee whose employment was terminated by the Company has entered into an agreement with the Company providing for
the full release of any claims against the Company or any related party arising out of such employment.

    	 

    	 

    

(f)
Section 2.15(f) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by the Company,
or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974, as amended
(“ERISA”). The Company has made all required contributions and has no liability to any such employee benefit plan,
other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA, and has complied in all material
respects with all applicable laws for any such employee benefit plan.

 

2.16
Tax Returns and Payments.

 

There
are no federal, state, county, local or foreign taxes due and payable by the Company which have not been timely paid. There are no accrued
and unpaid federal, state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have
been no examinations or audits of any tax returns or reports by any applicable federal, state, local or foreign governmental agency.
The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and
there are in effect no waivers of applicable statutes of limitations with respect to taxes for any year.

 

2.17
Insurance.

 

The
Company has in full force and effect insurance policies concerning such casualties as would be reasonable and customary for companies
like the Company, with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties
that might be damaged or destroyed.

 

2.18
Employee Agreements.

 

Each
current and former employee, consultant and officer of the Company has executed an agreement with the Company regarding confidentiality
and proprietary information substantially in the form or forms delivered to the Purchasers or their respective counsel (the “Confidential
Information Agreements”). No current or former Key Employee has excluded works or inventions from his or her assignment of inventions
pursuant to such Key Employee’s Confidential Information Agreement. Each current and former Key Employee has executed a non-competition
and non-solicitation agreement substantially in the form or forms delivered to the Purchasers or their respective counsel. The Company
is not aware that any of its Key Employees is in violation of any agreement described in this Section 2.18.

 

2.19
Permits.

 

The
Company has all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack of which
could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material respect under any of such
franchises, permits, licenses or other similar authority.

 

2.20
Corporate Documents.

    	 

    	 

    

The
Certificate of Incorporation and Bylaws of the Company as of the date of this Agreement are in the form provided to the Purchasers.

 

2..21
Disclosure.

 

The
Company has made available to the Purchasers all the information reasonably available to the Company that the Purchasers have requested
for deciding whether to acquire the Shares, including certain of the Company’s projections describing its proposed business plan
(the “Business Plan”). No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure
Schedule, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material fact,
to the Company’s knowledge, or, to the Company’s knowledge, omits to state a material fact necessary in order to make the
statements contained herein or therein not misleading in light of the circumstances under which they were made. The Business Plan was
prepared in good faith; however, the Company does not warrant that it will achieve any results projected in the Business Plan. It is
understood that this representation is qualified by the fact that the Company has not delivered to the Purchasers, and has not been requested
to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to
purchasers of securities.

 

2.22
S-1 Registration Statement.

 

On
December 10, 2021, the Company filed an S-1 registration statement with the Securities and Exchange Commission (“SEC”)
for the purpose of selling its common shares and warrants in connection with a firm commitment underwriting, as most recently amended
by Amendment No. 5 to Form S-1, filed with the SEC on April 22, 2022.

 

3.
Representations and Warranties of the Purchasers.

 

Each
Purchaser hereby represents and warrants to the Company, severally and not jointly,

that:

 

3.1
Authorization.

 

The
Purchaser has full power and authority to enter into this Agreement. This

Agreement,
when executed and delivered by the Purchaser, will constitute a valid and legally binding obligation of the Purchaser, enforceable against
such Purchaser in accordance with their terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent
conveyance and any other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies.

 

3.2
Purchase Entirely for Own Account.

 

This
Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s
execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by the Purchaser will be acquired for investment
for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof,
and that the Purchaser has no present intention of selling, granting any participation in, or otherwise distributing the same. By executing
this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement
with any Person to sell, transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. The
Purchaser has not been formed for the specific purpose of acquiring the Shares.

    	 

    	 

    

 

3.3
Disclosure of Information.

 

The
Purchaser has had an opportunity to discuss the Company’s business, management, financial affairs and the terms and conditions
of the offering of the Shares with the Company’s management and has had an opportunity to review the Company’s facilities.
The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 2 of this Agreement or
the right of the Purchasers to rely thereon.

 

3.4
Restricted Securities.

 

The
Purchaser understands that the Shares have not been, and will not be, registered under the Securities Act, by reason of a specific exemption
from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment
intent and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Shares are “restricted
securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the
Shares indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an
exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation
to register or qualify the Shares, or the Common Stock into which it may be converted, for resale. The Purchaser further acknowledges
that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not
limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company which are outside
of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy.

 

3.5
No Public Market.

 

The
Purchaser understands that no public market now exists for the Shares, and that the Company has made no assurances that a public market
will ever exist for the Shares.

 

3.6
Legends.

 

The
Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares will have the following legends:

 

“THE
SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH
A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER
THE SECURITIES ACT OF 1933.”

    	 

    	 

    

 

Any
legend required by the securities laws of any state to the extent such laws are applicable to the Shares represented by the certificate,
instrument, or book entry so legended.

 

3.7
Accredited Investor.

 

The
Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act.

 

3.8
Foreign Investors.

 

If
the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Code), the Purchaser hereby represents that it
has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the
Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii)
any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained,
and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer
of the Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the Shares will not violate any
applicable securities or other laws of the Purchaser’s jurisdiction.

 

3.9
CFIUS Foreign Person Status.

 

The
Purchaser is not a “foreign person” or a “foreign entity,” as defined in Section 721 of the Defense Production
Act of 1950, as amended, including all implementing regulations thereof (the “DPA”). The Purchaser is not controlled by a
“foreign person,” as defined in the DPA. The Purchaser does not permit any foreign person affiliated with the Purchaser,
whether affiliated as a limited partner or otherwise, to obtain through the Purchaser any of the following with respect to the Company:
(i) access to any “material nonpublic technical information” (as defined in the DPA) in the possession of the Company; (ii)
membership or observer rights on the Board of Directors or equivalent governing body of the Company or the right to nominate an individual
to a position on the Board of Directors or equivalent governing body of the Company; (iii) any involvement, other than through the voting
of shares, in the substantive decision-making of the Company regarding (x) the use, development, acquisition, or release of any “critical
technology” (as defined in the DPA), (y) the use, development, acquisition, safekeeping, or release of

“sensitive
personal data” (as defined in the DPA) of U.S. citizens maintained or collected by the Company, or (z) the management, operation,
manufacture, or supply of “covered investment critical infrastructure” (as defined in the DPA); or (iv) “control”
of the Company (as defined in the DPA).

 

No
General Solicitation.

 

Neither
the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including,
through a broker or finder (a) engaged in any general solicitation, or (b) published any advertisement in connection with the offer and
sale of the Shares.

    	 

    	 

    

 

3.11
Exculpation Among Purchasers.

 

The
Purchaser acknowledges that it is not relying upon any Person, other than the Company and its officers and directors, in making its investment
or decision to invest in the Company.

 

3.12
Residence.

 

If
the Purchaser is an individual, then the Purchaser resides in the state or province identified in the address of the Purchaser set forth
on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices
of the Purchaser in which its principal place of business is identified in the address or addresses of the Purchaser set forth on Exhibit
A.

 

3.13
No "Bad Actor" Disqualification.

 

The
Purchaser represents and warrants that neither (A) the Purchaser nor (B) any entity that controls the Purchaser or is under the control
of, or under common control with, the Purchaser, is subject to any Disqualification Event, except for Disqualification Events covered
by Rule 506(d)(2)(ii) or (iii) or (d)(3) under the Act and disclosed in writing in reasonable detail to the Company. The Purchaser represents
that the Purchaser has exercised reasonable care to determine the accuracy of the representation made by the Purchaser in this paragraph,
and agrees to notify the Company if the Purchaser becomes aware of any fact that makes the representation given by the Purchaser hereunder
inaccurate.

 

4.
Conditions to the Purchasers’ Obligations at Closing.

 

The
obligations of each Purchaser to purchase Shares at the Initial Closing or any subsequent Closing are subject to the following closing
deliverables unless otherwise waived:

 

4.1
Secretary’s Certificate.

 

The
Secretary of the Company shall have delivered to the Purchasers at the Closing a certificate certifying (i) the Certificate of Incorporation
and Bylaws of the Company as in effect at the Closing, and (ii) resolutions of the Board of Directors of the Company approving this Agreement.

 

5.
Conditions of the Company’s Obligations at Closing.

 

The
obligations of the Company to sell Shares to the Purchasers at the Initial Closing or any subsequent Closing are subject to the following
closing deliverables, unless otherwise waived: None.

    	 

    	 

    

6.
Covenants.

 

6.1
Delivery of Financial Statements.

 

The
Company shall deliver to each Purchaser:

 

(a)
as soon as practicable, but in any event within one hundred twenty (120) days after the end of each fiscal year of the Company (i) an
unaudited balance sheet as of the end of such year, (ii) unaudited statements of income and of cash flows for such year and (iii) an
unaudited statement of stockholders’ equity as of the end of such year;

 

(b)
as soon as practicable, but in any event within forty-five

(45)
days after the end of each quarter of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal
quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared
in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments; and (ii) not
contain all notes thereto that may be required in accordance with GAAP);

 

If,
for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period
the financial statements delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements
of the Company and all such consolidated subsidiaries.

 

(c)
Termination. The covenants set forth in this Section 6.1 shall terminate and be of no further force or effect (i) immediately
before the consummation of the initial public offering or (ii) when the Company first becomes subject to the periodic reporting requirements
of Section 12(g) or 15(d) of the Exchange Act.

 

6.2
Confidentiality.

 

Each
Purchaser agrees that such Purchaser will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor
or make decisions with respect to its investment in the Company) any confidential information obtained from the Company pursuant to the
terms of this Agreement (including notice of the Company’s intention to file a registration statement), unless such confidential
information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 6.3 by such Purchaser),(b)
is or has been independently developed or conceived by such Purchaser without use of the Company’s confidential information, or
(c) is or has been made known or disclosed to such Purchaser by a third party without a breach of any obligation of confidentiality such
third party may have to the Company; provided, however, that a Purchaser may disclose confidential information (i) to its attorneys,
accountants, consultants, and other professionals to the extent reasonably necessary to obtain their services in connection with monitoring
its investment in the Company; or (ii) to any existing Affiliate, partner, member, stockholder, or wholly owned subsidiary of such Purchaser
in the ordinary course of business, provided that such Purchaser informs such Person that such information is confidential and directs
such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, regulation, rule, court
order or subpoena, provided that such Purchaser promptly notifies the Company of such disclosure and takes reasonable steps to minimize
the extent of any such required disclosure.

    	 

    	 

    

 

6.3
Board of Directors.

 

(a)
Board of Directors Information Rights. Within ten (10) days of any meeting of the Board of Directors, the Company shall give Purchasers
copies of minutes, board books, consents and other materials resulting from or relating to any meeting of the Board of Directors, which
minutes, board books, consents and materials shall be appropriately redacted to protect information that is confidential and/or sensitive,
as reasonably determined by the Company. Any information provided to Purchasers shall be subject to the confidentiality agreement in
Section 6.2 of this Agreement.

 

(b)
Board of Directors Seat. If the Company’s gross revenue (determined in accordance with Section 1 of this Agreement) is less
than $6,000,000 for calendar year 2023, the Purchasers, in the aggregate and not individually, shall have the right to designate one
(1) individual (a “Nominee”), for nomination to the Board of Directors. The Purchasers shall submit the name of the
nominee to the Company no later than March 30, 2023. The Company shall include, and shall use its best efforts to cause the Board of
Directors (subject to the Board of Director’s fiduciary duties), whether acting through the nominating and corporate governance
committee or otherwise, to include, such Nominee, in the slate of nominees recommended to the Company’s stockholders for election
as a director at the next annual or special meeting of stockholders at or by which directors of the Company are to be elected.

 

7.
Miscellaneous.

 

7.1
Survival of Warranties.

 

Unless
otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers contained in or made pursuant
to this Agreement shall survive the execution and delivery of this Agreement and each Closing and shall in no way be affected by any
investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers or the Company.

 

7.2
Successors and Assigns.

 

The
terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the
parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective
successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement.

 

7.3
Governing Law.

 

This
Agreement shall be governed by the internal law of the State of Nevada, without regard to conflict of law principles that would result
in the application of any law other than the law of the State of Nevada.

    	 

    	 

    

7.4
Counterparts.

 

This
Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

Counterparts
may be delivered via electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g.,
www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered
and be valid and effective for all purposes.

 

7.5
Titles and Subtitles.

 

The
titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting
this Agreement.

 

7.6
Notices.

 

(a)
General. All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed
effectively given upon the earlier of actual receipt, or (a) personal delivery to the party to be notified, (b) when sent, if sent by
electronic mail during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid,
or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day
delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth
on the signature page or Exhibit A, or to such email address or address as subsequently modified by written notice given in accordance
with this Section 7.6.

 

(b)
Consent to Electronic Notice. Each Purchaser consents to the delivery of any stockholder notice pursuant to the Nevada Revised
Statues (the “NRS”), as amended or superseded from time to time, by electronic transmission pursuant to NRS 75.150(2) (or
any successor thereto) at the e-mail address set forth below such Purchaser’s name on the signature page or Exhibit A, as
updated from time to time by notice to the Company. To the extent that any notice given by means of electronic transmission is returned
or undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has
been provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each Purchaser agrees to
promptly notify the Company of any change in its e-mail address, and that failure to do so shall not affect the foregoing.

 

7.7
No Finder’s Fees.

 

Each
party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this transaction.
Each Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature
of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability
or asserted liability) for which each Purchaser or any of its officers, employees or representatives is responsible. The Company agrees
to indemnify and hold harmless each Purchaser from any liability for any commission or compensation in the nature of a finder’s
or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability)
for which the Company or any of its officers, employees or representatives is responsible.

    	 

    	 

    

 

7.8
Amendments and Waivers.

 

Except
as set forth in Section 1.3(a) of this Agreement, any term of this Agreement may be amended, terminated or waived only with the written
consent of the Company and each Purchaser.

 

7.9
Severability.

 

The
invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.

 

7.10
Delays or Omissions.

 

No
delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any
other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall
it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter
occurring; nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter
occurring.

Any
waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement,
or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only
to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded to any
party, shall be cumulative and not alternative.

 

7.11
Entire Agreement.

 

This
Agreement (including the Exhibits hereto), constitute the full and entire understanding and agreement between the parties with respect
to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties
are expressly canceled.

 

7.12
Termination of Closing Obligations.

 

Each
Purchaser shall have the right to terminate its obligations to complete the Initial Closing or a subsequent Closing, as the case may
be, if prior to the occurrence thereof, any of the following occurs:

 

(a)
the Company consummates a deemed liquidation event;

 

(b)
the closing of an initial public offering of the Company, in which case the Purchasers may terminate their obligations hereunder immediately
prior to, or contingent upon, such closing; or

    	 

    	 

    

(c)
the Company (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially
all of its property, (iii) makes an assignment for the benefit of creditors, (iv) institutes any proceedings under the United States
Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the
rights of creditors generally, or files a petition or answer seeking reorganization or an arrangement with creditors to take advantage
of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed
against it, or (v) becomes subject to any involuntary proceedings under the United States Bankruptcy Code or any other federal or state
bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, when proceeding
is not dismissed within thirty (30) days of filing, or have an order for relief entered against it in any proceedings under the United
States Bankruptcy Code.

 

 

 

The
parties

Dispute
Resolution.

 

 

7.13
(a) hereby irrevocably and unconditionally submit to the

jurisdiction
of the state courts of Nevada and to the jurisdiction of the United States District Court for the District of Nevada for the purpose
of any suit, action or other proceeding arising out of or based upon this Agreement,

 

(b)
agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of
Nevada or the United States District Court for the District of Nevada, and

 

(c)
hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim
that it is not subject personally to the jurisdiction of the abovenamed courts, that its property is exempt or immune from attachment
or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding
is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.

 

7.14
Market Standoff.

 

To
the extent requested by the Company or an underwriter of securities of the Company, the Purchaser and any permitted transferee thereof
shall not, without the prior written consent of the managing underwriters in the IPO, offer, sell, make any short sale of, grant or sell
any option for the purchase of, lend, pledge, otherwise transfer or dispose of (directly or indirectly), enter into any swap or other
arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership (whether any such transaction
is described above or is to be settled by delivery of Securities or other securities, in cash, or otherwise), any Securities or other
shares of stock of the Company then owned by the Purchaser or any transferee thereof, or enter into an agreement to do any of the foregoing,
for up to 180 days following the effective date of the registration statement of the IPO filed under the Securities Act. For purposes
of this paragraph, "Company" includes any wholly owned subsidiary of the Company into which the Company merges or consolidates.
The Company may place restrictive legends on the certificates representing the shares subject to this paragraph and may impose stop transfer
instructions with respect to the Securities and such other shares of stock of the Purchaser and any transferee thereof (and the shares
or securities of every other person subject to the foregoing restriction) until the end of such period. The Purchaser and any transferee
thereof shall enter into any agreement reasonably required by the underwriters to the IPO to implement the foregoing within any reasonable
timeframe so requested. The underwriters for any IPO are intended third party beneficiaries of this paragraph and shall have the right,
power and authority to enforce the provisions of this paragraph as though they were parties hereto.

 

[Signatures
on following page]

    	 

    	 

    

 

 

IN
WITNESS WHEREOF, the parties have executed this Common Stock Purchase Agreement as of the date first written above.

 

COMPANY:

 

SOS
HYDRATION INC.

PURCHASER:

 

 

 

 

 

 

Name:
James Mayo

Title:
Chief Executive Officer

 

Address:

Name:
Title:

 

Address:

 

1265
Bramwood pl, Unit 6 Longmont, CO 80501

[_]

 

    	 

    	 

    

EXHIBITS

 

 

 

	EXHIBIT
    A	SCHEDULE
    OF PURCHASERS
	EXHIBIT
    B	WARRANT
	EXHIBIT
    C	DISCLSOURE
    SCHEDULE
	EXHIBIT
    D	FORM
    OF COMMON STOCK PURCHASE WARRANT AMENDMENT

    	 

    	 

    

EXHIBIT
A

SCHEDULE
OF PURCHASERS

 

 

	Purchaser
    Name and Address	Number
    of Shares	Purchase
    Price (US$)

    	 

    	 

    

EXHIBIT
B 

WARRANT

    	 

    	 

    

EXHIBIT
C

DISCLOSURE
SCHEDULEExhibit
10.12

 

 

SOS
HYDRATION INC.

Victor
Andrade January 9, 2022 

Address:

Phone
Number

Email

Re:
Updated Offer of Employment by SOS Hydration Inc. 

Dear
Victor,

I
am very pleased to confirm our offer to you of full-time employment with SOS Hydration Inc., a Nevada corporation based in Longmont Colorado
(the “Company”), for the position of Chief Financial Officer in the United States. You will report directly
to and be supervised by the James Mayo. This offer is contingent upon the company successfully completing satisfactory reference and
background checks.

Your
first date of employment with the company shall be January 9, 2022. The terms of our offer and the benefits currently provided by the
Company are as follows:

		1.	Salary.
                                            You will be paid a salary of $150,000.00 per year (less withholding and other applicable
                                            deductions) and will be payable twice per month in accordance with the Company’s Employee
                                            Handbook attached hereto as Exhibit C.

		2.	Commission
                                            and Bonus Payments. You may be entitled, either now or in the future, to receive
                                            commissions or bonus payments that are paid purely upon your achievement of specific
                                            goals or objectives, and/or team/Company goals. If you are entitled to any such additional
                                            payment, the tasks, duties, revenue objectives and goals needed to be completed in order
                                            to qualify for such payment
                                            will be found in Exhibit A.

3.
       Benefits. Your Employee Handbook will provide you with details related to the employee
benefits

you
are entitled to.

4.
       Confidentiality. As an employee of the Company, you will have access to certain confidential

information
of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property
of the Company. To protect the interests of the Company, you will need to sign the Company's standard "Employee Invention Assignment
and Confidentiality Agreement" in the form attached hereto as Exhibit
B as a condition of your employment.

		5.	At
                                            Will Employment. You are agreeing that you understand that this Agreement does not constitute
                                            a contract of employment or obligate the Company to employ you for any stated period
                                            of time. You understand that you are an “at will” employee of the Company
                                            and that your employment can be terminated at any time, with or without notice and with or
                                            without cause, for any reason or for no reason, by either the Company or yourself. You acknowledge
                                            that any statements or representations to the contrary are ineffective, unless put into a
                                            writing signed by the Company. You further acknowledge that your participation in any benefit
                                            program is not to be construed as any assurance
                                            of continuing employment for any particular period of time.
                                            This Agreement shall be effective as of the first day of your employment by the Company
                                            as noted above.

		6.	Authorization
                                            to Work. Please note that because of employer regulations adopted in the Immigration
                                            Reform and Control Act of 1986, within three (3) business days of starting your new position
                                            you will need to present documentation demonstrating that you have authorization to work
                                            in the United States.

 

 

 

SOS
Hydration Inc., 1265 Bramwood Pl, Unit 6, Longwood CO 80501, USA.

Web:
www.sosrehydrate.com | Email: james@sosrehydrate.com| Phone: +1 (415) 815-7665

    	 

    	 

    

 

 

 

 

		7.	Arbitration.
                                            You and the Company shall submit to mandatory and exclusive binding arbitration of any
                                            controversy or claim arising out of, or relating to, this Agreement or any breach hereof,
                                            provided, however, that
                                            the parties retain their right to, and shall not be prohibited, limited or in any other way
                                            restricted from, seeking or obtaining equitable relief from a court having jurisdiction over
                                            the parties. Such arbitration shall be governed by the Federal Arbitration Act and conducted
                                            through the American Arbitration Association in the State of California, San Francisco County,
                                            before a single neutral arbitrator, in accordance with the National Rules for the Resolution
                                            of Employment Disputes of the American Arbitration
                                            Association in effect at that time. The parties may conduct only essential discovery prior
                                            to the hearing, as defined by the AAA arbitrator. The arbitrator shall issue a written decision
                                            that contains the essential findings and conclusions on which the decision is based. You
                                            shall bear only those costs of arbitration you would otherwise bear had you brought a claim
                                            covered by this Agreement in court. Judgment upon the determination or award rendered by
                                            the arbitrator may be entered in any court having jurisdiction thereof.

		8.	Acceptance.
                                            Your signature will acknowledge that you have read and understood and agreed to the terms
                                            and conditions of this offer letter and the attached documents, if any. Should you have anything
                                            else that you wish to discuss, please do not hesitate to call me.

We
look forward to the opportunity to welcome you to the Company.

 

 

Very
truly yours,

 

 

/S/JAMES
MAYO

James
Mayo, SOS Hydration Inc.

I
have read and understood this offer letter and hereby acknowledge, accept and agree to the terms as set forth above and further acknowledge
that no other commitments were made to me as part of my employment offer except as specifically set forth herein.

 

/S/
VICTOR ANDRADE

 

 

Victor
Andrade

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SOS
Hydration Inc., 1265 Bramwood Pl, Unit 6, Longwood CO 80501, USA.

Web:
www.sosrehydrate.com | Email: james@sosrehydrate.com| Phone: +1 (415) 815-7665

    	 

    	 

    

 

 

 

 

 

EXHIBIT
A 

Job
Description 

In
order for you to be eligible for any Commission or Bonus payments, you are expected to perform the tasks and duties as detailed in this
Job Description along with other tasks, duties, specific revenue objectives and other objectives for the year that may be agreed upon
between you and your supervisor. Bonus are usually team orientated based off company performance. 

If
you are entitled to receive any commission or bonus payments, the specific tasks, duties, specific revenue objectives and other objectives
will be documented as an Appendix to this Exhibit A by your supervisor. 

Bonus
payments are made for exceeding objectives not for meeting them. 

 

Objective:

To
support our growing business in the USA.

 

Job
description: 

 

•
Deliver on all finance activities

•
Implement and deliver on a set plan for expansion.

•
Be ready to set budget and work within budgets already set to achieve goals

• Ensure SOS hits and meets SCC requirements for being a public company

•
Deliver timely financial reporting that passes Audit

•
Assist CEO with budget planning and investor communications

•
Support the SOS board from a financial input perspective.

 

Required
skills: 

 

•
Finance experience

•
Food and beverage experience

•
Lead, work alongside, inspire and train the current team

•
As a senior member to help instill SOS process into the team

•
Ability to work independently. SOS believes in mission command.

•
Ability to multi-task and work under pressure

•
Good communication skills and customer facing skills

•
Very strong negotiation skills

•
Ability to do many other facets outside job description for the best benefit of a growing company

• Be flexible in work hours

 

Desired
skills: 

A
sense of humour 

 

 

 

 

 

SOS
Hydration Inc. 548 Market Street, #82331, San Francisco, CA 94104, USA. Web:
WWW.SOSHYDRATION.COM

    	 

    	 

    

 

 

 

EXHIBIT
B 

Employee
Invention Assignment and Confidentiality Agreement 

In
consideration of, and as a condition of my employment with SOS Hydration, Inc., a California corporation based in California (the “Company”),
I hereby represent to, and agree with the Company as follows:

1.
Purpose of Agreement. I understand that the Company is engaged in a continuous program of research, development, production and
marketing in connection with its business and that it is critical for the Company to preserve and protect its “Proprietary
Information” (as defined in Section 7 below), its rights in “Inventions” (as defined in Section
2 below) and in all related intellectual property rights. Accordingly, I am entering into this Employee Invention Assignment and Confidentiality
Agreement (this “Agreement”) as a condition of my employment with the Company, whether or not I am expected
to create inventions of value for the Company. 

2.
Disclosure of Inventions. I will promptly disclose in confidence to the Company all inventions, improvements, designs, original
works of authorship, formulas, processes, compositions of matter, computer software programs, databases, mask works and trade secrets
(the “Inventions”) that I make or conceive or first reduce to practice or create, either alone or jointly with
others, during the period of my employment, whether or not in the course of my employment,
and whether or not such Inventions are patentable, copyrightable or protectable as trade secrets. 

3.
Work for Hire; Assignment of Inventions. I acknowledge and agree that any copyrightable works prepared by me within the scope
of my employment are “works for hire” under the Copyright Act and that the Company will be considered the author and owner
of such copyrightable works. I agree that all Inventions that (i) are developed using equipment, supplies, facilities or trade secrets
of the Company, (ii) result from work performed by me for the Company, or (iii) relate to the Company’s business or current or
anticipated research and development (the “Assigned Inventions”), will be the sole and exclusive property of
the Company and are hereby irrevocably assigned by me to the Company. Attached
hereto as Appendix A is a list describing all inventions, original works of authorship, developments and trade secrets which were made
by me prior to the date of this Agreement, which belong to me and which are not assigned to the Company (“Prior Inventions”).
I acknowledge and agree that if I use any of my Prior Inventions in the scope of my employment, or include them in any product or service
of the Company, I hereby grant to the Company a perpetual, irrevocable, nonexclusive, world-wide, royalty-free license to use, disclose,
make, sell, copy, distribute, modify and create works based on, perform or display such Prior Inventions and to sublicense third parties
with the same rights. 

4.
Labor Code Section 2870 Notice. I have been notified and understand that the provisions of Sections 3 and 5 of this Agreement
do not apply to any Assigned Invention that qualifies fully under the provisions of Section 2870 of
the California Labor Code, which states as follows: 

ANY
PROVISION IN AN EMPLOYMENT AGREEMENT WHICH PROVIDES THAT AN EMPLOYEE SHALL ASSIGN, OR OFFER TO ASSIGN, ANY OF HIS OR HER RIGHTS IN AN
INVENTION TO HIS OR HER EMPLOYER SHALL NOT APPLY TO AN INVENTION THAT THE EMPLOYEE DEVELOPED ENTIRELY ON HIS OR HER OWN TIME WITHOUT
USING THE EMPLOYER’S EQUIPMENT, SUPPLIES, FACILITIES, OR TRADE SECRET INFORMATION EXCEPT FOR THOSE INVENTIONS THAT EITHER: (1)
RELATE AT THE TIME OF CONCEPTION OR REDUCTION TO PRACTICE OF THE INVENTION TO THE EMPLOYER’S BUSINESS, OR ACTUAL OR DEMONSTRABLY
ANTICIPATED
RESEARCH OR DEVELOPMENT OF THE EMPLOYER; OR (2) RESULT FROM ANY WORK PERFORMED BY THE EMPLOYEE FOR THE EMPLOYER. TO THE EXTENT
A PROVISION
IN AN EMPLOYMENT AGREEMENT PURPORTS TO REQUIRE AN EMPLOYEE TO ASSIGN AN INVENTION
OTHERWISE EXCLUDED FROM BEING REQUIRED TO
BE ASSIGNED UNDER CALIFORNIA LABOR CODE SECTION 2870(a), THE PROVISION IS AGAINST
THE PUBLIC POLICY OF THIS STATE AND IS UNENFORCEABLE. 

5.
Assignment of Other Rights. In addition to the foregoing assignment of Assigned Inventions to the Company, I hereby irrevocably
transfer and assign to the Company: (i) all worldwide patents, patent applications, copyrights, mask works, trade secrets and other intellectual
property rights, including but not limited to rights in databases, in any Assigned Inventions, along with any registrations of or applications
to register such rights; and (ii) any and all “Moral Rights” (as defined below) that I may have in or with respect to any
Assigned Inventions. I also hereby forever waive and agree never to assert any and all Moral Rights I may have in or with respect to
any Assigned Inventions, even after 

SOS
Hydration Inc. 548 Market Street, #82331, San Francisco, CA 94104, USA. Web:
WWW.SOSHYDRATION.COM

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]